Conversely, inhibiting NGF can also produce safety issues; NGF neutralization with monoclonal antibodies, such as Tanezumab for osteoarthritis, has been linked to arthralgia and incidents of rapidly progressive osteoarthritis, prompting the need for stringent exposure management and imaging-based surveillance in any program that perturbs this pathway [107]. The gene discussed is NGF; the disease is osteoarthritis.